Jingyuan Wen,Gregory Brian Thomas,Mike John Bickerdike
申请号：
US13471150
公开号：
US08496963B2
申请日:
2012.05.14
申请国别(地区):
US
年份:
2013
代理人:
摘要：
Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.
